YS vs. PRPH, ETON, ONCY, VACC, QTTB, ACRS, MIST, CMRX, LFVN, and BYSI
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include ProPhase Labs (PRPH), Eton Pharmaceuticals (ETON), Oncolytics Biotech (ONCY), Vaccitech (VACC), Q32 Bio (QTTB), Aclaris Therapeutics (ACRS), Milestone Pharmaceuticals (MIST), Chimerix (CMRX), LifeVantage (LFVN), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.
In the previous week, ProPhase Labs had 2 more articles in the media than YS Biopharma. MarketBeat recorded 5 mentions for ProPhase Labs and 3 mentions for YS Biopharma. YS Biopharma's average media sentiment score of 1.58 beat ProPhase Labs' score of 0.16 indicating that YS Biopharma is being referred to more favorably in the media.
ProPhase Labs has lower revenue, but higher earnings than YS Biopharma.
YS Biopharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -82.18%. YS Biopharma's return on equity of 0.00% beat ProPhase Labs' return on equity.
52.6% of YS Biopharma shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 26.1% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
YS Biopharma has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.
ProPhase Labs received 113 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 50.22% of users gave ProPhase Labs an outperform vote.
YS Biopharma presently has a consensus price target of $5.25, suggesting a potential upside of 452.63%. ProPhase Labs has a consensus price target of $11.00, suggesting a potential upside of 115.26%. Given YS Biopharma's higher possible upside, equities analysts plainly believe YS Biopharma is more favorable than ProPhase Labs.
Summary
YS Biopharma beats ProPhase Labs on 9 of the 14 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
